Studies in various solid tumors have shown that the response rate to PD-L1/PD-1 inhibitor treatment correlates with overexpression of PD-L1 in patients’ tumor tissues, serving as a predictive biomarker for immunotherapy sensitivity (52–54). Here, CD274 is linked to neoplasm.